This biographical article is written like a résumé. (March 2014) |
Stuart C. Sealfon | |
---|---|
Born | New York City, United States | April 17, 1956
Alma mater | Princeton University, Columbia University |
Scientific career | |
Fields | neurology |
Institutions | Mount Sinai Medical Center |
Stuart C. Sealfon is an American neurologist who studies the mechanisms of both the therapeutic and adverse effects of drugs. He was an early adopter of the use of massively parallel qPCR and fluorescent in situ hybridization to characterize cell response state[1] and his research accomplishments have included the identification of the primary structure of the gonadotropin-releasing hormone receptor, finding new signaling pathways activated by drugs for Parkinson's disease, elucidating the mechanism of action of hallucinogens and finding a new brain receptor complex implicated in schizophrenia as a novel target for antipsychotics.[2][3][4]
Sealfon is the Glickenhaus Professor and Chairman of the Department of Neurology at The Mount Sinai School of Medicine in New York City. Sealfon also serves as director of Mount Sinai's Center for Translational Systems Biology. Additionally, he is both Professor of Neurobiology and Professor of Pharmacology and Systems Therapeutics.[5]
Sealfon is the author of multiple book chapters and is the editor of Receptor Molecular Biology, Volume 25 (ISBN 0121852954). He has contributed to more than 100 original research articles and holds two patents.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)